WO2011050638A1 - 一种比马前列素晶体及其制备方法和用途 - Google Patents
一种比马前列素晶体及其制备方法和用途 Download PDFInfo
- Publication number
- WO2011050638A1 WO2011050638A1 PCT/CN2010/075574 CN2010075574W WO2011050638A1 WO 2011050638 A1 WO2011050638 A1 WO 2011050638A1 CN 2010075574 W CN2010075574 W CN 2010075574W WO 2011050638 A1 WO2011050638 A1 WO 2011050638A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- crystal form
- bimatoprost
- preparation
- ray powder
- powder diffraction
- Prior art date
Links
- AQOKCDNYWBIDND-FTOWTWDKSA-N bimatoprost Chemical compound CCNC(=O)CCC\C=C/C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1\C=C\[C@@H](O)CCC1=CC=CC=C1 AQOKCDNYWBIDND-FTOWTWDKSA-N 0.000 title claims abstract description 108
- 229960002470 bimatoprost Drugs 0.000 title claims abstract description 104
- 238000002360 preparation method Methods 0.000 title claims abstract description 31
- 238000000634 powder X-ray diffraction Methods 0.000 claims abstract description 53
- 239000013078 crystal Substances 0.000 claims description 108
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 claims description 43
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 42
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 30
- 238000000034 method Methods 0.000 claims description 30
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 29
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims description 29
- 238000000113 differential scanning calorimetry Methods 0.000 claims description 25
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 24
- 238000003756 stirring Methods 0.000 claims description 22
- 239000002904 solvent Substances 0.000 claims description 21
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 claims description 19
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 18
- 238000002329 infrared spectrum Methods 0.000 claims description 16
- 238000002156 mixing Methods 0.000 claims description 16
- 239000012454 non-polar solvent Substances 0.000 claims description 11
- 239000003208 petroleum Substances 0.000 claims description 11
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 claims description 10
- 239000003937 drug carrier Substances 0.000 claims description 9
- OFBQJSOFQDEBGM-UHFFFAOYSA-N Pentane Chemical compound CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 claims description 8
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 claims description 7
- KXKVLQRXCPHEJC-UHFFFAOYSA-N acetic acid trimethyl ester Natural products COC(C)=O KXKVLQRXCPHEJC-UHFFFAOYSA-N 0.000 claims description 7
- 150000001875 compounds Chemical class 0.000 claims description 7
- JMMWKPVZQRWMSS-UHFFFAOYSA-N isopropanol acetate Natural products CC(C)OC(C)=O JMMWKPVZQRWMSS-UHFFFAOYSA-N 0.000 claims description 7
- 229940011051 isopropyl acetate Drugs 0.000 claims description 7
- 239000008194 pharmaceutical composition Substances 0.000 claims description 7
- WMOVHXAZOJBABW-UHFFFAOYSA-N tert-butyl acetate Chemical compound CC(=O)OC(C)(C)C WMOVHXAZOJBABW-UHFFFAOYSA-N 0.000 claims description 7
- 239000003814 drug Substances 0.000 claims description 5
- 150000003180 prostaglandins Chemical class 0.000 claims description 4
- 208000010412 Glaucoma Diseases 0.000 claims description 3
- 125000005233 alkylalcohol group Chemical group 0.000 claims description 3
- -1 isopropyl acetate Ester Chemical class 0.000 claims description 3
- 239000000243 solution Substances 0.000 description 16
- 229960004592 isopropanol Drugs 0.000 description 14
- 238000010521 absorption reaction Methods 0.000 description 13
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 12
- 239000000203 mixture Substances 0.000 description 12
- 239000007787 solid Substances 0.000 description 11
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 9
- 238000002425 crystallisation Methods 0.000 description 7
- 230000008025 crystallization Effects 0.000 description 7
- 238000004128 high performance liquid chromatography Methods 0.000 description 7
- 238000010438 heat treatment Methods 0.000 description 6
- 238000003760 magnetic stirring Methods 0.000 description 6
- 239000000463 material Substances 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- GWYFCOCPABKNJV-UHFFFAOYSA-N isovaleric acid Chemical compound CC(C)CC(O)=O GWYFCOCPABKNJV-UHFFFAOYSA-N 0.000 description 5
- 238000001228 spectrum Methods 0.000 description 5
- 238000009835 boiling Methods 0.000 description 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 230000015556 catabolic process Effects 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 238000006731 degradation reaction Methods 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- PXGPLTODNUVGFL-BRIYLRKRSA-N (E,Z)-(1R,2R,3R,5S)-7-(3,5-Dihydroxy-2-((3S)-(3-hydroxy-1-octenyl))cyclopentyl)-5-heptenoic acid Chemical class CCCCC[C@H](O)C=C[C@H]1[C@H](O)C[C@H](O)[C@@H]1CC=CCCCC(O)=O PXGPLTODNUVGFL-BRIYLRKRSA-N 0.000 description 2
- NTIZESTWPVYFNL-UHFFFAOYSA-N Methyl isobutyl ketone Chemical compound CC(C)CC(C)=O NTIZESTWPVYFNL-UHFFFAOYSA-N 0.000 description 2
- UIHCLUNTQKBZGK-UHFFFAOYSA-N Methyl isobutyl ketone Natural products CCC(C)C(C)=O UIHCLUNTQKBZGK-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 239000007884 disintegrant Substances 0.000 description 2
- 238000004090 dissolution Methods 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000013355 food flavoring agent Nutrition 0.000 description 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- 239000002798 polar solvent Substances 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 238000005070 sampling Methods 0.000 description 2
- 238000001308 synthesis method Methods 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- HTSGKJQDMSTCGS-UHFFFAOYSA-N 1,4-bis(4-chlorophenyl)-2-(4-methylphenyl)sulfonylbutane-1,4-dione Chemical compound C1=CC(C)=CC=C1S(=O)(=O)C(C(=O)C=1C=CC(Cl)=CC=1)CC(=O)C1=CC=C(Cl)C=C1 HTSGKJQDMSTCGS-UHFFFAOYSA-N 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010030043 Ocular hypertension Diseases 0.000 description 1
- 206010030348 Open-Angle Glaucoma Diseases 0.000 description 1
- 241000364051 Pima Species 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 239000002220 antihypertensive agent Substances 0.000 description 1
- 239000008365 aqueous carrier Substances 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000003796 beauty Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 238000007707 calorimetry Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 239000007857 degradation product Substances 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 238000005265 energy consumption Methods 0.000 description 1
- 125000001033 ether group Chemical group 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- NLFBCYMMUAKCPC-KQQUZDAGSA-N ethyl (e)-3-[3-amino-2-cyano-1-[(e)-3-ethoxy-3-oxoprop-1-enyl]sulfanyl-3-oxoprop-1-enyl]sulfanylprop-2-enoate Chemical compound CCOC(=O)\C=C\SC(=C(C#N)C(N)=O)S\C=C\C(=O)OCC NLFBCYMMUAKCPC-KQQUZDAGSA-N 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 210000000720 eyelash Anatomy 0.000 description 1
- 210000001061 forehead Anatomy 0.000 description 1
- 230000009477 glass transition Effects 0.000 description 1
- 230000003779 hair growth Effects 0.000 description 1
- 239000012456 homogeneous solution Substances 0.000 description 1
- 238000009776 industrial production Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000004410 intraocular pressure Effects 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 238000010606 normalization Methods 0.000 description 1
- 239000006179 pH buffering agent Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 239000008057 potassium phosphate buffer Substances 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 239000012925 reference material Substances 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000011877 solvent mixture Substances 0.000 description 1
- 238000013112 stability test Methods 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C405/00—Compounds containing a five-membered ring having two side-chains in ortho position to each other, and having oxygen atoms directly attached to the ring in ortho position to one of the side-chains, one side-chain containing, not directly attached to the ring, a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, and the other side-chain having oxygen atoms attached in gamma-position to the ring, e.g. prostaglandins ; Analogues or derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C233/00—Carboxylic acid amides
- C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C233/02—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having nitrogen atoms of carboxamide groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
- C07C2601/08—Systems containing only non-condensed rings with a five-membered ring the ring being saturated
Definitions
- the present invention relates to the field of chemical pharmaceutics, and in particular to a novel bimatoprost crystal and a preparation method and use thereof. Background technique
- PGF2a Analog (Z)-7-[(1R, 2R, 3R, 5S)-3, 5-Dihydroxy-2- [(E, 3S)-3-hydroxy-5-phenylpent-1-enyl ]cyclopentyl]-N-ethylhept-5-enamide (Bimatoprost, bimatoprost) has been used to reduce open-angle glaucoma and ocular hypertension that are intolerant or insensitive to other ocular hypotensive agents. The intraocular pressure of the patient. At the same time, it also has a good application prospect in beauty.
- the X-ray powder diffraction (XRPD) pattern has characteristic peaks at the following 2 ⁇ angles: 5.4, 6.2, 10.9, 11.3, 13.1, 16.6, 17.5, 18.3, 18.6, 18.9, 19.4, 19.1, 19.9, 20.1 , 20.9, 21.6, 22.7 and 28.2.
- bimatoprost is hardly soluble in a solvent such as ethyl acetate, t-butyl acetate, methylene chloride or methyl isobutyl ketone under low temperature conditions, so that in the prior art crystallization, The solvent is dissolved at a near boiling point or a boiling point temperature, and then cooled to crystallize.
- a solvent such as ethyl acetate, t-butyl acetate, methylene chloride or methyl isobutyl ketone under low temperature conditions
- US 2009/016359 A1 provides a process for the preparation of Form B, mainly by bimatoprost in ethyl acetate, tert-butyl acetate, dichloromethane, methyl isobutyl ketone, toluene, acetonitrile, diethyl ether, n-heptane.
- a single solvent such as methyl tertiary ether, or in a solvent mixture of these solvents with ethers (ether, tert-ether and diisopropyl ether)
- ethers ether, tert-ether and diisopropyl ether
- the present invention aims to provide a novel bimatoprost crystal.
- Another object of the present invention is to provide a process for the preparation of the novel bimatoprost crystal.
- a further object of the invention is to provide the use of the novel bimatoprost crystals.
- a fourth object of the present invention is to provide a pharmaceutical composition containing a novel bimatoprost crystal
- a Bimatoprost Form A having a structure as shown in Formula I, wherein the Form A has an X-ray powder diffraction (XRPD) pattern at the following 2 ⁇ angles Characteristic peak: 3.2 ⁇ 0.2. , 19.9 ⁇ 0.2 °, 2 ° and 22.8 ⁇ 0.2 °;
- the X-ray powder diffraction (XRPD) pattern of the crystal form A has a characteristic peak at the following 2 ⁇ angle: 5 ⁇ 5 ⁇ 0 ⁇ 2°, 11 ⁇ 4 ⁇ 0 ⁇ 2°, 16.7 ⁇ 0.2° and 17.6 ⁇ 0.2°.
- the X-ray powder diffraction (XRPD) pattern of the crystalline form has a characteristic peak at the following 2 ⁇ angle: 6 ⁇ 3 ⁇ 0 ⁇ 2. , 8 ⁇ 3 ⁇ 0 ⁇ 2. , 9 ⁇ 5 ⁇ 0 ⁇ 2. , 10 ⁇ 9 ⁇ 0 ⁇ 2. , 12.6 ⁇ 0.2° .13.8 ⁇ 0.2 °, 18.4 ⁇ 0.2°, 19.0 ⁇ 0.2°, 21.7 ⁇ 0.2°, 23.9 ⁇ 0.2°, 26.2 ⁇ 0.2°, 27.7 ⁇ 0.2°, 28.3 ⁇ 0.2°, 30.4 ⁇ 0.2° , 32.4 ⁇ 0.2 °, 35.3 ⁇ 0.2 °.
- the X-ray powder diffraction (XRPD) pattern of the crystalline form has peaks at the following 2 ⁇ ⁇ 0.1° reflection angles: 19.9, 20.8 and 22.8; preferably, the crystal form A
- the X-ray powder diffraction (XRPD) pattern is shown below as 2 ⁇ ⁇ 0.
- the reflection angle also has peaks: 3.2, 5.5, 11.4, 16.7 and 17.6; more preferably, the X-ray powder diffraction of the crystalline form (XRPD)
- the graph below shows 2 ⁇ ⁇ 0.
- the reflection angle has peaks: 6.3, 8.3, 9.5, 10.9, 12.6.13.8, 18.4, 19.0, 21.1, 23.9, 26.2, 27.1, 28.3, 30.4, 32.4, 35.3 .
- the bimatoprost crystalline form provided by the present invention has a maximum peak at 66.5-70.5 °C on a differential scanning calorimetry (DSC); more preferably, the crystal form A has a differential scan as shown in FIG. Calorimetry Atlas (DSC).
- the bimatoprost crystal form A provided by the present invention has an infrared spectrum as shown in Fig. 4.
- a process for the preparation of bimatoprost crystal form A as provided by the invention as described above comprising the steps of:
- the non-polar solvent is selected from the group consisting of one or more of the following: pentane, hexane, heptane, and petroleum ether.
- the temperature of the mixing is 10 30 °C.
- the stirring time is at 150 hours.
- the stirring temperature is from 25 ° C to 1 CTC; more preferably, in the step (3), the stirring temperature is minus 25 ° C, minus 10 ° C, 0 ° C, 5 ° C, or 10 ° C.
- the compound of the formula I is mixed with the ratio of the pimaprost and the solvent to a ratio of 1:5 to 100 to obtain a solution 1.
- step (2) the mixing ratio of the solution 1 to the non-polar solvent is 0.3-2:1.
- the bimatoprost of the oil described in the step (1) is obtained by the following steps: mixing the bimatoprost and the alcohol solvent as shown in the formula I, and concentrating to dryness An oily bimatoprost is obtained; the alcohol solvent is a C1-C4 linear or branched alkyl alcohol.
- the bimatoprost crystal form A provided by the invention as described above for the preparation of a medicament for the treatment of glaucoma.
- a pharmaceutical composition comprising the bimatoprost crystal form A of the invention as described above and a pharmaceutically acceptable carrier.
- a method of preparing a pharmaceutical composition according to the invention as described above the method comprising the steps of:
- the bimatoprost crystal form A provided by the present invention as described above and a pharmaceutically acceptable carrier are mixed to obtain the pharmaceutical composition provided by the present invention as described above. Accordingly, the present invention provides a novel bimatoprost crystal which is stable and can be dissolved and crystallized at a relatively low temperature.
- Figure 1 shows an X-ray powder diffraction pattern of Form B disclosed in US 2009/016359 A1.
- Fig. 2 shows an X-ray powder diffraction pattern of the bimatoprost crystal form A prepared by the present invention.
- Figure 3 shows a differential scanning calorimetry diagram of the bimatoprost crystal form A prepared by the present invention.
- FIG. 4 shows the infrared spectrum of the bimatoprost crystal form A prepared by the present invention. detailed description
- bimatoprost was first dissolved in an alcohol solvent at a lower temperature, and then concentrated under reduced pressure at a lower temperature to dryness to obtain an oily bimatoprost, and then at a lower temperature.
- the solution is dissolved in acetone, butanone, methyl acetate, ethyl acetate, isopropyl acetate, t-butyl acetate, dichloromethane, or isopropanol at a temperature, and finally crystals are precipitated by adding a non-polar solvent. This is a good way to avoid the drawback of high temperature dissolution and also save energy.
- a compound of formula I or “bimatoprost” is used interchangeably and refers to a PGF2a analog (Z)-7-[(1R, 2R, 3R, 5S)-3, 5-dihydroxyl - 2- [ (E, 3S) - 3-hydroxy-5-phenylpenta-1 - -N-ethylhept-5-enamide, the structure is as follows:
- the compound of the formula I in the present invention means bimatoprost and can be obtained by a conventional method in the art. Preparation method of bimatoprost crystal form A
- the inventors have found through intensive research that the oil of bimatoprost can be compared with acetone, butanone, methyl acetate, ethyl acetate, isopropyl acetate, t-butyl acetate, dichloromethane or isopropyl at lower temperatures.
- the bimatoprost solution is diluted with a non-polar solvent pentane or hexane or heptane or petroleum ether or a mixture thereof, followed by crystallization, and by changing the crystallization temperature and molar concentration. , cooling rate or stirring, crystallization time and other factors, found that bimatoprost precipitated a single crystal form A, further indicating that crystal form A is another stable crystal form, and the crystallization yield of this method is high.
- the present invention provides a preparation of the aforementioned Pima A method of crystals, the method comprising the steps of:
- bimatoprost described in step (1) is crystalline or amorphous.
- the alcohol solvent is a C1-C4 linear or branched alkyl alcohol, preferably methanol, ethanol and isopropanol.
- the temperature of mixing the bimatoprost with the solvent is 10-30 ° C, preferably
- the concentration under reduced pressure is 10-30 ° C, preferably 20-30 ° C.
- the polar solvent is selected from the group consisting of acetone, butanone, methyl acetate, ethyl acetate, isopropyl acetate, t-butyl acetate, dichloromethane, or Isopropanol, preferably acetone, ethyl acetate, dichloromethane, or isopropanol;
- the temperature at which the bimatoprost is mixed with the solvent is 10-30 ° C, preferably 20-30 ° C.
- the mixing ratio of the bimatoprost and the solvent of the oil is 1:5 - 100 (m: v).
- the non-polar solvent is selected from one of the following or a mixture thereof: pentane, hexane, heptane or petroleum ether, preferably n-hexane, n-heptane and petroleum ether.
- the mixing ratio of the solution 1 and the non-polar solvent is 0.3-2:1 ( V:V ).
- the stirring time is 1 to 50 h, preferably 10 to 25 h.
- the stirring temperature is from 25 to 10 ° C below zero, preferably from 10 to 5 ° C below zero.
- step 3 If the starting material is bimatoprost in oil, then only step 3 is required. (See, in particular, Examples 4, 5, 10, 13). The nature was studied.
- X-ray powder diffraction also known as “X-ray polycrystalline diffraction (XRPD)
- XRPD X-ray polycrystalline diffraction
- An X-ray powder diffractometer is used to generate a series of diffraction patterns when X-rays are transmitted through the crystal. The different diffraction lines and their intensities in the spectrum are determined by the atomic groups of a certain structure, thereby determining the specific crystal structure of the crystal.
- Methods for determining X-ray powder diffraction of crystals are known in the art. For example, using a Bruker D8 Advanced model X-ray powder diffractometer, a copper radiation target is used to acquire the spectrum at a scan rate of 2° per minute.
- the bimatoprost crystal form A of the present invention has a specific crystal morphology and has a specific characteristic peak in an X-ray powder diffraction (XRPD) pattern.
- XRPD X-ray powder diffraction
- the XRPD pattern of the prostaglandin crystal form A of the present invention has characteristic peaks at the following 2 ⁇ angles: 3.2 ⁇ 0.2 °, 19.9 ⁇ 0.2 °, 20.8 ⁇ 0.2 ° and 22.8 ⁇ 0.2°; in a preferred embodiment, the map also has characteristic peaks at the following 2 corners: 5.5 ⁇ 0.2°, 11.4 ⁇ 0.2°, 16.7 ⁇ 0.2° and 17.6 ⁇ 0.2°; in another preferred embodiment, The map also has characteristic peaks at the following 2 corners: 6.3 ⁇ 0.2 °, 8.3 ⁇ 0.2 °, 9.5 ⁇ 0.2 °, 10.9 ⁇ 0.2 °, 12.6 ⁇ 0.2 °, 13.8 ⁇ 0.2 °, 18.4 ⁇ 0.2 °,
- the peak of the 2 ⁇ reflection angle on the X-ray powder diffraction (XRPD) pattern of the prostaglandin crystal form A of the present invention is a special feature, which is related to the X-ray powder diffraction (XRPD) of the crystal form B reported in US 2009/016359 A1. There are significant differences in the characteristic peaks at the reflection angle of 2 ⁇ on the graph.
- the absorption intensity of the spectrum and the angle of 2 ⁇ are compared as follows: (1) The crystal form A prepared by the present invention has a 3.2 ⁇ 0.2° peak of medium-intensity characteristic absorption, while the crystal form B reported in US2009/016359A1 has no peak of absorption; 2) The characteristic absorption intensity of 5.5 ⁇ 0.2 ° in crystal form A is medium absorption intensity, while the crystal form B is the strongest characteristic absorption; (3) the strongest characteristic absorption in crystal form A is 19.9 ⁇ 0.2° Peak, while in Form B, it is divided into three peaks of 19.4 ⁇ 0.2°, 19.7 ⁇ 0.2° and 19.9 ⁇ 0.2° of the second characteristic absorption intensity; (4) 20.8 ⁇ 0.2° second strong in Form A Characteristic absorption peak, but in crystal form B is split into two peaks of 20.7 ⁇ 0.2° and 20.9 ⁇ 0.2° of the third characteristic absorption intensity; (5) 16.7 ⁇ 0.2° and 17.6 ⁇ 0.2° in crystal form A The low-intensity characteristic absorption peak, while in the crystal form B, the crack is divided into
- DSC Differential calorimetric scanning analysis
- a DSC scan of the crystal can be obtained by using a DSC Q20 differential scanning calorimeter at a temperature increase rate of 10 ° C per minute from 25 ° C to 300 ° C.
- the bimatoprost crystal form A obtained by the method of the present invention has a maximum peak at around 66.5-70.5 ° C as measured by DSC, and preferably the bimatoprost crystal form A of the present invention has Figure 3 shows a substantially consistent DSC spectrum, more preferably with a maximum peak at 67.91 °C.
- Infrared profiling can also be used to determine the crystal structure, the method of which is known in the art.
- the infrared spectrum of the bimatoprost crystal form A of the present invention shows the following wave number characteristic peaks : 3415.03 cm - 3326.69 cm - 3085.84 cm - 2914.06 cm - 2865.73 cm - 1 , 1619.61 cm - 1 , 1546.22 cm - 1 , 1496.54 cm - 1 , 1455.38 cm - 1 , 1372.19 cm - 1 , 1346.23 cm - 1 , 1317.02 cm — 1 , 1290.25 cm— 1 , 1248.99 cm— 1 , 1151.57 cm— 1 , 1097.45 cm— 1 , 1054.67 cm— 1 , 1027.58 cm— 1 , 975.78 cm— 1 , 920.47 cm— 1 , 859.10 cm— 1 , 698.34 cm — 1 , 596.08 cm—preferably has an infrared spectrum substantially identical to that of FIG. 4.
- the bimatoprost crystal form A of the present invention has a specific stability and is advantageous for preservation.
- the inventors compared the stability of Form A prepared by the process of the present invention with Form B prepared by the prior art by a stability test. The data indicates that Form A was sealed at 40 ° C for 4 days and showed no degradation, while Form B showed significant degradation. Its degradation products are Compound II and Compound III. This shows that the stability of the crystal form A prepared by the method of the invention is obvious
- the bimatoprost crystal form A prepared by the invention has better stability, is easy to store and use, and has high purity, and thus can be provided as a raw material medicine or used for preparing a medicament for treating and preparing glaucoma.
- the present invention is also directed to a composition comprising Bimatoprost Form A of the present invention, said composition comprising an effective amount of Bimatoprost Form A, and a pharmaceutically acceptable carrier.
- the term “containing” or “including” includes “comprising”, “consisting essentially of”, and “consisting of”.
- the term “effective amount” refers to an amount that is functional or active to a human and/or animal and that is acceptable to humans and/or animals.
- the term "pharmaceutically acceptable” means a substance that is suitable for use in humans and/or animals without excessive adverse side effects (e.g., toxicity, irritation, and allergies), i.e., a material having a reasonable benefit/risk ratio.
- pharmaceutically acceptable carrier refers to a carrier for the administration of a therapeutic agent, including various excipients and diluents.
- the term refers to pharmaceutical carriers which are not themselves essential active ingredients and which are not excessively toxic after administration. Suitable carriers are well known to those of ordinary skill in the art. A full discussion of pharmaceutically acceptable excipients can be found in Remington's Pharmaceut i cal Sc ences, Mack Pub. Co., N. J. 1991.
- the "pharmaceutically acceptable carrier” is selected from the group consisting of: a filler, a disintegrant, a lubricant, a glidant, an effervescent agent, a flavoring agent, a coating material, an excipient, or a gentle/ Controlled release agent.
- the pharmaceutically acceptable carrier can contain liquids such as water, saline, glycerol and ethanol.
- auxiliary substances such as fillers, disintegrants, lubricants, glidants, effervescent agents, wetting or emulsifying agents, flavoring agents, pH buffering substances and the like may also be present in these carriers.
- these materials can be formulated in a non-toxic, inert, andpharmaceutically acceptable aqueous carrier medium wherein the pH is usually from about 5 to about 8, preferably, the pH is from about 6 to about 8.
- the pH is usually from about 5 to about 8
- the pH is from about 6 to about 8.
- the present invention provides a novel stable bimatoprost crystal.
- the method for preparing a novel bimatoprost crystal provided by the invention has low energy consumption, stable yield and easy industrial production.
- the invention is further illustrated below in conjunction with specific embodiments. It is to be understood that the examples are not intended to limit the scope of the invention.
- the experimental methods in which the specific conditions are not indicated in the following examples are usually carried out according to conventional conditions or according to the conditions recommended by the manufacturer. All percentages, ratios, ratios, or parts are by weight unless otherwise indicated.
- the unit of weight percent by volume in the present invention is well known to those skilled in the art and, for example, refers to the weight of the solute in a 100 ml solution.
- HPLC purity refers to the percentage of the peak area of a compound of formula I as a percentage of all peak areas obtained by HPLC normalization based on the obtained chromatogram.
- HPLC detection method is as follows:
- the sample of bimatoprost crystal A prepared in Example 4 (0.8 g, HPLC purity: 99.7 %) was divided into 4 equal portions and sealed at 40 ° C for 1 day, 2 days, 3 days and 4 days, respectively. Sampling analysis, HPLC purity were 99.7%, 99.7%, 99.7% and 99.7%, respectively.
- the sample of bimatoprost crystal B obtained in Example 2 (0.8 g, HPLC purity 99.6%) was divided into 4 equal portions and sealed at 40 ° C for 1 day, 2 days, 3 days and 4 days, respectively. Sampling analysis, HPLC purity were 99.4%, 99.2%, 99.1% and 98.7%, respectively.
- the above data demonstrates that Form A of the present invention is more stable than Form B prepared in the prior art.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Ophthalmology & Optometry (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Steroid Compounds (AREA)
Description
Claims
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2012535603A JP5734302B2 (ja) | 2009-11-02 | 2010-07-30 | ビマトプロストの結晶およびその製造方法と用途 |
EP10826001.9A EP2497766A4 (en) | 2009-11-02 | 2010-07-30 | CRYSTALLINE FORM OF BIMATOPROST AND MANUFACTURING METHOD THEREFOR AND USE THEREOF |
US13/505,360 US8664275B2 (en) | 2009-11-02 | 2010-07-30 | Crystalline form of Bimatoprost, preparation method and use thereof |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN200910198080.5 | 2009-11-02 | ||
CN200910198080 | 2009-11-02 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2011050638A1 true WO2011050638A1 (zh) | 2011-05-05 |
Family
ID=43921298
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CN2010/075574 WO2011050638A1 (zh) | 2009-11-02 | 2010-07-30 | 一种比马前列素晶体及其制备方法和用途 |
Country Status (6)
Country | Link |
---|---|
US (1) | US8664275B2 (zh) |
EP (1) | EP2497766A4 (zh) |
JP (1) | JP5734302B2 (zh) |
KR (1) | KR20120081227A (zh) |
CN (1) | CN102050772B (zh) |
WO (1) | WO2011050638A1 (zh) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9238621B2 (en) | 2011-06-02 | 2016-01-19 | Chinoin Zrt | Processes for the preparation of prostaglandin amides |
US20210317059A1 (en) * | 2017-05-24 | 2021-10-14 | Biomedical Analysis Center, Academy Of Military Medical Sciences | New method for preparing 2-tert-butyl-4-methoxyphenol and new crystal form thereof |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102596097B (zh) | 2009-06-03 | 2015-05-20 | 弗赛特实验室有限责任公司 | 一种眼插入件 |
SI2911623T1 (sl) | 2012-10-26 | 2019-12-31 | Forsight Vision5, Inc. | Oftalmični sistem za podaljšano sproščanje zdravila v oko |
AU2014241201A1 (en) * | 2013-03-27 | 2015-10-15 | Forsight Vision5, Inc. | Bimatoprost ocular silicone inserts and methods of use thereof |
JP2017502089A (ja) | 2014-01-10 | 2017-01-19 | マニスティー パートナーズ エルエルシーManistee Partners Llc | 偏頭痛の処置 |
US20160296532A1 (en) | 2015-04-13 | 2016-10-13 | Forsight Vision5, Inc. | Ocular Insert Composition of a Semi-Crystalline or Crystalline Pharmaceutically Active Agent |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005058812A2 (en) | 2003-12-19 | 2005-06-30 | Johnson Matthey Public Limited Company | Prostaglandin synthesis |
US7157590B2 (en) | 2001-05-31 | 2007-01-02 | Finetech Laboratories Ltd. | Process for the preparation of 17-phenyl-18,19,20-thinor-pgf 2a and its derivatives |
US7166730B2 (en) | 2000-01-27 | 2007-01-23 | Fine Tech Laboratories, Ltd | Process for the preparation of prostaglandin derivatives |
WO2007111806A2 (en) | 2006-03-23 | 2007-10-04 | Massachusetts Eye And Ear Infirmary | Cyclopentane heptanoic acid compounds for reducing body fat |
US20070282006A1 (en) | 2002-02-04 | 2007-12-06 | Woodward David F | Method of enhancing hair growth |
US20090016359A1 (en) | 2007-07-11 | 2009-01-15 | Samsung Electronics Co., Ltd. | System and method for processing high definition video data to be transmitted over a wireless medium |
US20090163596A1 (en) * | 2006-08-29 | 2009-06-25 | Arie Gutman | Bimatoprost crystalline form I |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5352708A (en) | 1992-09-21 | 1994-10-04 | Allergan, Inc. | Non-acidic cyclopentane heptanoic acid, 2-cycloalkyl or arylalkyl derivatives as therapeutic agents |
US5688819A (en) * | 1992-09-21 | 1997-11-18 | Allergan | Cyclopentane heptanoic acid, 2-cycloalkyl or arylalkyl derivatives as therapeutic agents |
-
2010
- 2010-07-30 US US13/505,360 patent/US8664275B2/en active Active
- 2010-07-30 WO PCT/CN2010/075574 patent/WO2011050638A1/zh active Application Filing
- 2010-07-30 CN CN2010102473266A patent/CN102050772B/zh active Active
- 2010-07-30 JP JP2012535603A patent/JP5734302B2/ja not_active Expired - Fee Related
- 2010-07-30 KR KR1020127014310A patent/KR20120081227A/ko active Search and Examination
- 2010-07-30 EP EP10826001.9A patent/EP2497766A4/en not_active Withdrawn
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7166730B2 (en) | 2000-01-27 | 2007-01-23 | Fine Tech Laboratories, Ltd | Process for the preparation of prostaglandin derivatives |
US7157590B2 (en) | 2001-05-31 | 2007-01-02 | Finetech Laboratories Ltd. | Process for the preparation of 17-phenyl-18,19,20-thinor-pgf 2a and its derivatives |
US20070282006A1 (en) | 2002-02-04 | 2007-12-06 | Woodward David F | Method of enhancing hair growth |
WO2005058812A2 (en) | 2003-12-19 | 2005-06-30 | Johnson Matthey Public Limited Company | Prostaglandin synthesis |
WO2007111806A2 (en) | 2006-03-23 | 2007-10-04 | Massachusetts Eye And Ear Infirmary | Cyclopentane heptanoic acid compounds for reducing body fat |
US20090163596A1 (en) * | 2006-08-29 | 2009-06-25 | Arie Gutman | Bimatoprost crystalline form I |
US20090016359A1 (en) | 2007-07-11 | 2009-01-15 | Samsung Electronics Co., Ltd. | System and method for processing high definition video data to be transmitted over a wireless medium |
Non-Patent Citations (1)
Title |
---|
"Remington's Pharmaceutical Sciences", 1991, MACK PUB. CO. |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9238621B2 (en) | 2011-06-02 | 2016-01-19 | Chinoin Zrt | Processes for the preparation of prostaglandin amides |
US9573892B2 (en) | 2011-06-02 | 2017-02-21 | Chinoin Zrt | Processes for the preparation of prostaglandin amides |
JP2017075165A (ja) * | 2011-06-02 | 2017-04-20 | キノイン・ゼー・エル・テー | プロスタグランジンアミドの新規製造方法 |
US9856213B2 (en) | 2011-06-02 | 2018-01-02 | Chinoin Zrt | Processes for the preparation of prostaglandin amides |
US20210317059A1 (en) * | 2017-05-24 | 2021-10-14 | Biomedical Analysis Center, Academy Of Military Medical Sciences | New method for preparing 2-tert-butyl-4-methoxyphenol and new crystal form thereof |
US11655201B2 (en) * | 2017-05-24 | 2023-05-23 | Biomedical Analysis Center, Academy Of Military Medical Sciences | Method for preparing 2-tert-butyl-4-methoxyphenol and new crystal form thereof |
Also Published As
Publication number | Publication date |
---|---|
CN102050772B (zh) | 2013-08-21 |
US8664275B2 (en) | 2014-03-04 |
JP5734302B2 (ja) | 2015-06-17 |
EP2497766A4 (en) | 2014-10-15 |
US20120270946A1 (en) | 2012-10-25 |
JP2013509358A (ja) | 2013-03-14 |
KR20120081227A (ko) | 2012-07-18 |
EP2497766A1 (en) | 2012-09-12 |
CN102050772A (zh) | 2011-05-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2011050638A1 (zh) | 一种比马前列素晶体及其制备方法和用途 | |
JP7145931B2 (ja) | 化合物の結晶多形、その製造方法及び用途 | |
JP6239977B2 (ja) | 肥満治療用の医薬組成物 | |
JP2005522503A (ja) | N−(トランス−4−イソプロピルシクロヘキシルカルボニル)−d−フェニルアラニンの結晶形 | |
TW200813081A (en) | Salts and crystal modifications | |
JP2012519715A (ja) | アゴメラチンの新規結晶形態vi、製造方法及びその応用 | |
JP2002519422A (ja) | パロキセチンメタンスルホネート | |
JP2014510139A (ja) | 固体形態のhiv阻害剤 | |
JP2019526628A (ja) | セニクリビロクメシレートの固体形態及びセニクリビロクメシレートの固体形態を製造するプロセス | |
JP2015508090A (ja) | 固体形態のダビガトランエテキシレートメシレート及びその調製方法 | |
EA020545B1 (ru) | Соли карбоновой кислоты 2-амино-3-карбэтоксиамино-6-(4-фторбензиламино)пиридина | |
US20170342037A1 (en) | A CRYSTAL FORM OF NEPTINIB di-P-METHYLBENZENESULFONATE, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL COMPOSITION CONTAINING SAME | |
GB2495458A (en) | Preparation method for and uses of carboprost tromethamine crystal | |
EP2767533B1 (en) | Derivative of butylphthalide and preparation method and use thereof | |
JP5523699B2 (ja) | 新規な結晶性のアトルバスタチンヘミカルシウム塩の多形相 | |
WO2012010092A1 (zh) | 一种肽类物质的晶体及其制备方法和用途 | |
CN113004355B (zh) | 呋喃酮糖苷类化合物、其药物组合物、制备方法及应用 | |
EP2066677B1 (en) | Pyridooxazepine progesteron receptor modulators | |
WO2018022797A1 (en) | Dermatological formulations of 2-(2-ethoxy-2-oxoethyl)(methyl)amino-2-oxoethyl 5-(tetradecyloxy)furan-2-carboxylate | |
JP6894490B2 (ja) | ベラプロスト−314d結晶形及びその調製方法 | |
JP7512405B2 (ja) | 2-[(4s)-8-フルオロ-2-[4-(3-メトキシフェニル)ピペラジン-1-イル]-3-[2-メトキシ-5-(トリフルオロメチル)フェニル]-4h-キナゾリン-4-イル]酢酸のカリウム塩 | |
CN111057069B (zh) | 一种环状化合物、其应用及组合物 | |
CN109535060B (zh) | 一种刺猬通路抑制剂及其制备方法和应用 | |
JP2012509929A (ja) | 多型 | |
WO2021097650A1 (zh) | 奥利司他与氨基酸的共晶体及包含该共晶体的药物组合物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 10826001 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2012535603 Country of ref document: JP |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
REEP | Request for entry into the european phase |
Ref document number: 2010826001 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2010826001 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 20127014310 Country of ref document: KR Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 13505360 Country of ref document: US |